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Abstract: Fluorescence emission, polarization and subcellular localization of methylene blue 
(MB) were studied in four cancerous and two normal human brain cell lines. Fluorescence 
emission and polarization images were acquired and analyzed. The co-localization of MB 
with mitochondria, lysosomes and nuclei of the cells was evaluated. Glioblastoma cells 
exhibited significantly higher MB fluorescence polarization compared to normal astrocytes. 
Preferential accumulation of MB in mitochondria of glioblastoma cells may explain higher 
fluorescence polarization values in cancer cells as compared to normal. These findings may 
lead to the development of a quantitative method for the detection of brain cancer in single 
cells. 
© 2019 Optical Society of America under the terms of the OSA Open Access Publishing Agreement 
1. Introduction 
More than 23,000 new cases of malignant brain tumors are expected to be diagnosed in 2019 
in the United States; approximately 18,000 individuals will die from the disease [1]. Gliomas 
account for approximately 80% of the malignant primary brain tumors, including high-grade, 
fast-growing glioblastomas. Glioblastoma multiform (GBM) is the most common and lethal 
intracranial neoplasm in adults [2]. 
In the majority of cases, brain cancers are diagnosed using histopathology, which relies on 
the qualitative morphological assessment of tissues and cells, i.e., visual recognition of 
differences in appearance of cancerous and normal structures. Histopathologic analysis is 
subjective by nature, being strongly dependent on the training and experience of the 
pathologist involved. In addition, this method is time-consuming and expensive, as it requires 
the use of multiple stains and extensive tissue processing. Therefore, the search for objective, 
quantitative markers of brain cancer, as well as for the methods of cancer detection that could 
be utilized in vivo, remains a hot topic in cancer research [3,4]. 
Different imaging and spectroscopic approaches to cellular-level characterization of 
biological specimens are being explored. Recent reports described Raman scattering signals 
being registered from living cells, with potential applications to cancer diagnosis [5–8] and 
intraoperative brain tumor delineation [9]. Combined reflectance and fluorescence confocal 
microscopy using exogenous contrast agents has been used to distinguish gliomas from 
normal brain tissue [10]. Detection of brain neoplasms using fluorescence signals from 
protoporphyrin-IX (PpIX) using 5-aminolevulinic acid (ALA) has been proposed [11]. Skala 
et al. and Sun et al. demonstrated that NADH fluorescence lifetime imaging (FLIM) could be 
utilized as a quantitative marker for cancer by measuring the fluorescence lifetime [12,13]. 
Our group is investigating the potential of fluorescence polarization (FP) imaging [14] for 
cancer detection. Specifically, we focus on FP exhibited by exogenous methylene blue (MB), 
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a phenothiazinium dye approved by the United States Food and Drug Administration for 
several clinical indications [15,16]. Previously, we demonstrated that MB enhanced contrast 
of brain neoplasms [17,18]. We have also shown that MB FP is significantly elevated in 
cancerous skin, breast and brain tissues [19–22]. More recently, we developed quantitative 
imaging techniques permitting FP analysis of single living cells. We showed that cultured 
human breast cancer cells exhibited significantly higher MB FP as compared to normal breast 
cells [23]. We also observed higher FP in renal fine-needle aspiration biopsy samples [24]. 
In this study we investigated MB FP of cultured human brain cells. We tested four 
glioblastoma cell lines and two normal astrocyte cell lines. Multimodal confocal microscopy 
was used to provide MB fluorescence emission and quantitative FP images of the cells. In 
addition, we performed co-localization experiments to evaluate the subcellular accumulation 
of MB in the brain cells. 
2. Materials and methods 
2.1 Cell culture and handling 
Human glioblastoma cell lines U87-MG, U118-MG, and U251-MG were obtained from the 
American Type Culture Collection (ATCC, Manassas, VA, USA). The primary glioblastoma 
cell line, 5075-MG, was provided by Dr. Alonzo Ross (University of Massachusetts Medical 
School, Worcester, MA). Two normal human astrocyte (NHA) cell lines, Clonetics-NHA and 
Gibco-NHA, were purchased from Lonza (Walkersville, MD) and Life Technologies 
(Carlsbad, CA, USA), respectively. 5075-MG and U251-MG cells were maintained as a 
monolayer culture in Dulbecco’s modified Eagle’s medium (DMEM, Life Technologies, 
Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (ATCC, Manassas, VA, 
USA) and 1% sodium pyruvate (Life Technologies, Carlsbad, CA, USA). U87-MG, U118-
MG and Gibco-NHA were cultured as monolayer in DMEM (Life Technologies, Carlsbad, 
CA, USA) supplemented with 10% fetal bovine serum. Clonetics-NHA was cultured with 
Astrocyte Growth Medium (AGM) BulletKit (Lonza, Walkersville, MD). All cells were 
grown at 37°C in 5% CO2-humidified atmosphere in 75 cm
2 flasks (Life Technologies, 
Carlsbad, CA, USA). When the cells reached 80% confluency, they were rinsed with 
phosphate-buffered saline (PBS) (Life Technologies, Carlsbad, CA, USA) and harvested with 
0.25% trypsin- ethylenediaminetetraacetic acid (EDTA) (Life Technologies, Carlsbad, CA, 
USA) solution. After centrifuging, the cells were plated in glass-bottom 4-well 35 mm Petri 
dishes (In Vitro Scientific, Mountain View, CA, USA) at a density of 105 cells per well. The 
cells were allowed to attach for 24 hours before imaging. All cell lines underwent a maximum 
of ten passages. 
All of the cells were cultured at Wellman Center for Photomedicine, except for the 
primary glioblastoma cell line, 5075-MG, which was cultured at the University of 
Massachusetts Medical School. 
The cells were transported to the Advanced Biophotonics Laboratory at UMASS Lowell 
for imaging and analysis. During transportation, cells were kept at 37°C in Leibovitz’s L-15 
medium (ATCC, Manassas, VA, USA). Prior to staining and imaging, cells were allowed to 
rest in the incubator (AR36L, Percival Scientific, Perry, IA, USA) for 40 min at a temperature 
of 37°C and relative humidity (RH) of 95% for recovery. Then the cells were stained with 
0.05 mg/ml aqueous solution of MB (0.3 ml per well) for 20 minutes. After staining, the cells 
were rinsed three times with PBS (Life Technologies, Carlsbad, CA, USA) to reduce 
background fluorescence. Confocal images of the cells were acquired at the ambient 
temperature of 18°C. The imaging time of each plate was limited to 30 min, and all plates 
were imaged within 6 hours after delivery. During the wait time, the cells were kept in the 
incubator in L-15 medium at a temperature of 37° C and RH of 95%. 
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2.2 Multimodal confocal imaging 
The point scanning multimodal confocal imaging system is illustrated in Fig. 1. A linearly 
polarized collimated beam emitted by a 642 nm diode laser (Micro Laser Systems, Garden 
Grove, CA) was used for illumination. The laser beam was scanned across x and y directions 
using a polygon mirror (Lincoln Laser, Phoenix, AZ) and a galvanometric mirror (General 
Scanning Inc., Billerica, MA), respectively. The scanning rate was set to 7 frames per second. 
The laser beam was focused onto the imaging plane by a 63X/1.4NA oil immersion objective 
(Carl Zeiss, Oberkochen, Germany) which provided a field of view of 205 µm2. Fluorescence 
signal emitted from the sample was reflected by a 12-degree dichroic mirror (Iridian Spectral 
Technologies, Ottawa, Ontario, Canada) with a reflection band between 670 – 740 nm and 
focused onto a 200 µm diameter pinhole. A 690 nm bandpass filter with full width at half 
maximum of 40 nm (Chroma Technology Corp., Bellows Falls, VT) was used before the 
pinhole to further reject the excitation light. Co- and cross-polarized components of the 
fluorescence emission were separated by a polarizing beam splitter (Karl Lambrecht Co., 
Chicago, IL) and simultaneously registered by two photomultiplier tubes (PMT) (Hamamatsu, 
Japan). Elastically scattered light was transmitted though the dichroic mirror, deflected by a 
non-polarizing beam splitter (Tower Optical, Boynton Beach, FL) and focused onto the 200 
µm diameter pinhole of the reflectance PMT. Signal was recorded as 8-bit gray-scale intensity 
images. The system yielded lateral resolution better than 0.9 µm and axial resolution of 2 µm. 
 
Fig. 1. Schematic of the point scanning confocal fluorescence polarization imaging system. 1 – 
642 nm laser, 2 – dichroic mirror, 3 – polygon mirror, 4 – galvanometric mirror, 5 – objective, 
6 – sample plane, 7 – focusing lens, 8 – fluorescence filter, 9 – pinhole, 10 – polarizing beam 
splitter, 11 – PMT for cross-polarized fluorescence, 12 – PMT for co-polarized fluorescence, 
13 – computer. 
2.3 System calibration 
The G factor, which characterizes the sensitivity of the detection channels to polarization, was 
measured with MB solution (Akorn, Inc., Lake Forest, IL) in phosphate buffered saline (PBS) 
and glycerol. The system’s G factor was determined to be G = 0.75, following the formula for 






= ×  (1) 
where vvF  corresponds to the fluorescence emission with vertically polarized excitation and 
vertically polarized emission, hvF  - horizontally polarized excitation and vertically polarized 
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emission, vhF  - vertically polarized excitation and horizontally polarized emission, and hhF  - 
horizontally polarized excitation and horizontally polarized emission. 
To validate the G factor, fluorescence polarization of each solution was calculated and 
confirmed with a commercial spectrofluorometer (FluoroMax-4, Horiba, Edison, NJ). 
2.4 Data processing 
Fluorescence polarization analysis was performed using MetaMorph software (Molecular 
Devices, Sunnyvale, CA). Co- and cross-polarized fluorescence emission images were 
thresholded to remove the background and saturated pixels. The low threshold value was 
selected to be 2, and the high threshold value was selected to be 254. For each cell area, 
fluorescence emission values were determined from co-polarized ( )F/ /  and cross-polarized 












where G is the calibration coefficient determined using formula (1). The fluorescence 
polarization value of each cell was obtained by averaging over 5 measurements. Data was 
averaged over each plate, and then averaged over all the plates to get average fluorescence 
polarization of each cell line. 
Fluorescence polarization images were generated in ImageJ (http://rsb.info.nih.gov/ij) 
using co-polarized ( )F/ /  and cross-polarized ( )F⊥  fluorescence images. Before image 
calculation, background was corrected, and images were converted to 32-bit [26]. 
Fluorescence sum ( )F G F/ / ⊥+ ×  and difference ( )F G F/ / ⊥− ×  images were generated using 









 image was then 
calculated using Ratio Plus. NucMed plugin was used to assign pseudo colors to the 
fluorescence polarization image. Color range was set from 0.10 to 0.34. 
2.5 Cell viability assay 
After imaging, the cells were stained with 0.4% trypan blue (Sigma-Aldrich, St. Louis, MO) 
and counted under a light microscope (PrimoVert, Carl Zeiss Microscopy, Peabody, MA) to 
confirm cell viability. MB stained cells appeared light blue under the microscope, whereas 
cells stained with both MB and trypan blue appeared purple and were considered dead. Plates 
with viability > 95% were selected for analysis. 
2.6 Co-localization experiments 
Previously published manuscripts [27–33] have reported that MB preferentially accumulates 
in several different intracellular organelles, including mitochondria, lysosomes, and nuclei. 
To quantitatively investigate the degree of MB co-localization with the nucleus, 
mitochondria, and lysosomes in the cell lines, we conducted the following experiments. 
LysoTracker Yellow HCK-123 (Life Technologies) was diluted with growth medium to a 
final concentration of 100 nM. MitoTracker Green FM (Life Technologies) was dissolved as 
1mM stock in DMSO and diluted with growth medium to a final concentration of 50 nM. 
Incubation time with LysoTracker and MitoTracker was 30 min. Cells were first stained with 
organelle trackers, and then stained with 0.05 mg/ml MB for 20 min under the same 
conditions as for the fluorescence polarization imaging experiments. After incubation with the 
trackers and MB, the cells were labeled for 5 minutes with a nuclei stain, 2 µg/ml Hoechst-
33342 (Life Technologies). Fluorescence emission images of live cells were recorded through 
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a confocal microscope (IX81, Olympus, Tokyo, Japan) with 40X water immersion objective 
lens. Images were acquired using Olympus FV10-ASW software (Olympus, Tokyo, Japan). 
During imaging, cells were kept in L-15 medium at 37°C. The degree of MB co-localization 
with different organelles was evaluated using the Coloc 2 plugin in Image J software. Regions 
of interest (ROIs) were manually selected to outline the organelles. Subcellular co-
localization of MB to nuclei, mitochondria and lysosomes was quantified using Pearson’s R 
values, which were generated for all the imaged cells. For each cell line, the data were 
averaged over all the imaged cells. 
2.7 Statistical analysis 
To quantify the significance of differences in fluorescence polarization values obtained in the 
fluorescence polarization imaging experiments, and Pearson’s R values obtained in MB 
localization experiments, the data were statistically evaluated using a mixed effects linear 
model [34]. Estimates of the means and standard errors were obtained for each cell line. The 
significance of the differences between the cancer and normal cell lines was assessed. P < 
0.001 was considered significant. 
3. Results 
In total, we imaged the MB fluorescence emission and polarization in 1839 individual 
cultured human brain cells, including 1054 for glioblastoma cell lines and 785 for normal 
astrocyte lines. In particular, in the cancerous cells lines, U87-MG, U118-MG, 5075-MG, and 
U251-MG we imaged 441, 101, 298, and 214 cells, respectively. From the normal cell lines, 
we imaged 620 cells from Clonetic-NHA and 165 cells from Gibco-NHA. The results are 
summarized in Table 1. They demonstrate a pronounced difference in fluorescence 
polarization values between glioblastoma cells and astrocytes. Overall, the average MB FP in 
glioblastoma cells was higher than that in astrocytes for all the cancer – normal cell line 
comparisons. As shown in columns 3 and 4 of Table 1, the glioblastoma cell lines, including 
U87-MG, U118-MG, U251-MG and primary 5075-MG cells had average FP values of 25.25 
± 0.09 x10−2, 24.39 ± 0.15 x10−2, 24.92 ± 0.11 x10−2 and 24.30 ± 0.09 x10−2, respectively. 
The normal Clonetics-NHA had an average FP value of 21.55 ± 0.08 x10−2, which is 
comparable to the average value of 21.46 ± 0.12 x10−2 exhibited by Gibco-NHA. The 
minimal differences in FP values of 13% were obtained for 3 cancer/normal cell line pairs, 
including U118MG/Clonetic NHA, 5075MG/Clonetic NHA and 5075MG/Gibco NHA. The 
maximal differences in FP values of 18% were obtained for U87MG/Gibco NHA. Even 
though these differences are not large on an absolute scale, the small standard errors, shown 
in column 4 of Table 1, ensure excellent separation between glioblastoma cells and normal 
astrocytes. Statistical analysis confirmed that the differences between astrocytes and 
glioblastoma cells were significant for all cell lines pairs (p<0.0001). 
3.1 Fluorescence emission and polarization of MB 
Representative fluorescence emission and polarization (FP) images of two normal human 
astrocyte and four human glioblastoma cell lines (U87-MG, U118-MG, 5075-MG, and U251-
MG) are presented in Figs. 2 and 3, respectively. Figures 2(a)-(f) show fluorescence emission 
images of cells after 20 min incubation with MB. In all cell lines, the MB fluorescence signal 
was observed to arise from the entire cell area. However, the fluorescence emission was not 
distributed evenly across the cell area. In particular, nuclei of the cells exhibited stronger 
fluorescence. This observation is consistent with known nuclear staining properties of MB 
[35]. 
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Table 1. Cell line information and percentage differences of MB FP between 




















U87-MG 441 25.25 × 10-
2 0.09 × 10-2 18 17 <0.0001 <0.0001 
U118-MG 101 24.39 × 10-




0.09 × 10-2 13 13 <0.0001 <0.0001 
U251-MG 214 24.92 × 10-




2 0.08 × 10-2 
    
Gibco-NHA 165 21.46 × 10-
2 0.12 × 10-2 
 
Fig. 2. Methylene blue (MB) fluorescence emission images of normal astrocytes (a, b) and 
glioblastoma cells (c-f). Cells were stained with 0.05 mg/ml MB. Bar: 50 µm. 
The nucleoli and nuclear envelope can be identified clearly in all the cells. Many 
glioblastoma cells (Figs. 2(c)-(f)), especially primary 5075-MG cells (Fig. 2(e)), display high 
mitotic activity. Outside the nuclei, a strong signal was observed from the mitochondria and 
lysosomes of the cells. Corresponding quantitative FP images are presented in Figs. 3(a)-(f). 
The scale bar color range corresponds to the fluorescence polarization values between 0.10 
and 0.34. Figure 3(a) and Fig. 3(b) reveal that the FP in the nucleus of astrocytes was higher, 
as compared to the rest of the cell. On the other hand, the FP of the GBM cells was 
distributed more homogeneously and remained high over the entire cell volume (Figs. 3(c)-
(f)). 
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Fig. 3. Methylene blue (MB) fluorescence polarization images of normal astrocytes (a, b) and 
glioblastoma cells (c-f). Cells were stained with 0.05 mg/ml MB. Bar: 50 µm 
The FP images in Fig. 3 demonstrate that the MB FP differences between cancer and 
normal cells were more pronounced in the region outside of the cell nucleus. 
3.2 Subcellular Localization of MB 
Results of the co-localization experiments are shown in Fig. 4. For each experiment we 
imaged and analyzed 31 – 56 cells in each of the different cell lines. The degree of MB co-
localization within the cell organelles were quantified by Pearson’s R-value. As shown in Fig. 
4(a), the degree of MB co-localization with the nuclei is uniformly high among all the cell 
lines. The mean Pearson’s R-values for U87-MG, U118-MG, 5075-MG and U251-MG were 
0.34 ± 0.03, 0.39 ± 0.03, 0.37 ± 0.03 and 0.5 ± 0.03, respectively. For the normal cell lines, 
the R-values were 0.037 ± 0.02 (Clonetics-NHA) and 0.47 ± 0.03 (Gibco-NHA). No 
significant differences were observed between astrocytes and glioblastoma cells. MB co-
localization with lysosomes is presented in Fig. 4(b). It varied across different cell lines. In 
particular, U87-MG, U118-MG and Gibco-NHA yielded comparable Pearson’s R-values of 
0.36 ± 0.03, 0.39 ± 0.03, and 0.34 ± 0.03, respectively. Weaker degrees of co-localization 
were observed in 5075-MG, U251-MG, and Clonetics-NHA. Their respective R-values were 
0.2 ± 0.02, 0.17 ± 0.03, and 0.1 ± 0.03 respectively. Figure 4(c) demonstrates the results of 
MB co-localization with mitochondria. R-values of glioblastoma cell lines, U87-MG, U118-
MG, 5075-MG, and U251-MG were, 0.70 ± 0.05, 0.42 ± 0.04, 0.29 ± 0.04, and 0.36 ± 0.04, 
respectively. It can be appreciated that the cell line with highest FP, U87-MG, demonstrates 
the highest degree of MB co-localization with the mitochondrial-tracker, whereas the 
glioblastoma which presented the lowest fluorescence polarization value, cell line 5075-MG, 
also yielded the lowest degree of MB co-localization with the mitochondrial tracker. This 
correlation suggests that the intracellular binding sites of MB play an important role in 
determining the average FP values within the cells. Both normal cell lines, Clonetic NHA and 
Gibco-NHA showed a low degree of MB co-localization with mitochondria and yielded 
Pearson’s R-values of 0.17 ± 0.04 and 0.11 ± 0.04, respectively. Thus MB has significantly 
higher (p < 0.0001) degrees of co-localization with mitochondria in glioblastoma cell lines, as 
compared to those in normal astrocytes in all the normal / cancer cell line comparisons. The 
affinity of MB to the mitochondria of glioblastoma cells can explain the higher FP observed 
from cancer cells. 
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Fig. 4. Degree of co-localization between MB staining and the stain used to visualize (a) 
nucleus (Hoechst-33342), (b) lysosomes (LysoTracker) and (c) mitochondria (MitoTracker). N 
is the number of cells analyzed. *p<0.0001 
4. Discussion 
This study was performed to evaluate multimodal optical imaging for potential use in the 
detection of brain cancer at the cellular level. Previously, we showed that dye-enhanced 
confocal reflectance and fluorescence emission imaging could provide morphological details 
of normal and cancerous brain tissue, comparable to that of H&E histopathology [17,18]. In 
accordance with our results obtained for brain tissues, fluorescence emission imaging of 
single cells yielded morphological features similar to those of histopathology. The results of 
MB fluorescence polarization imaging reveal that cancerous brain cells exhibited significantly 
higher MB FP as compared to normal astrocytes (p<0.0001). We observed that the FP from 
cancer cells was homogeneously distributed over the entire cell volume, whereas the FP of 
the normal cells was higher in the nucleus. To validate this observation, we used fluorescence 
emission images to select cells with clearly outlined nuclei and performed subcellular FP 
analysis. In particular, we segmented the nuclei of the cells and determined the average MB 
FP values of the cells with nuclei excluded from the analysis. Then we determined 
fluorescence polarization of the cell nuclei of these cells. Subcellular FP analysis of 630 cells 
was conducted. This included 391 cancer cells (U87-MG: 105, U118-MG: 80, 5075-MG: 
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101, U251-MG: 105) and 239 normal cells (Clonetic-NHA: 136, Gibco-NHA: 103). The 
results of this analysis are presented in Table 2a-c. 
Table 2. Cell line information, MB FP values and percentage differences of MB FP 
between glioblastoma cells and normal astrocytes. (a) Analysis of the entire cell; (b) 
analysis of these cells with nuclei excluded; (c) analysis of the cell nuclei. 
a Cell Line 
# of 
Cells 
Whole Cell FP 
%diff in FP 
with 
Gibco-NHA










U87-MG 105 25.61 ± 0.15 x10-
2 19 18 
<0.0001 <0.0001  
U118-MG 80 24.79 ± 0.17 x10-
2 15 14 
 
5075-MG 101 24.51 ± 0.16 x10-
2 14 13 
 
U251-MG 105 25.67 ± 0.16 x10-
2 20 18 
 




Gibco-NHA 103 21.47 ± 0.15 x10-
2 






%diff in FP 
with 
Gibco-NHA









U87-MG 105 25.13 ± 0.13 x10-
2 23 19 
<0.0001 <0.0001  
U118-MG 80 24.15 ± 0.15 x10-
2 19 15 
 
5075-MG 101 23.94 ± 0.14 x10-
2 17 13 
 
U251-MG 105 25.00 ± 0.15 x10-
2 23 18 
 




Gibco-NHA 103 20.43 ± 0.14 x10-
2 




%diff in FP 
with 
Gibco-NHA









U87-MG 105 25.90 ± 0.13 x10-
2 14 12 
<0.0001 <0.0001  
U118-MG 80 24.62 ± 0.16 x10-
2 8 6 
 
5075-MG 101 24.45 ± 0.14 x10-
2 8 6 
 
U251-MG 105 25.76 ± 0.15 x10-
2 14 12 
 




Gibco-NHA 103 22.73 ± 0.13 x10-
2 
As shown in Table 2a, column 3, Gibco-NHA had an average FP value of 21.47 ± 0.15 
x10-2, which is comparable to the average value of Clonetics-NHA (21.70 ± 0.15 x10-2). The 
glioblastoma cell lines, including U87-MG, U118-MG, U251-MG and primary 5075-MG 
cells had average FP of 25.61 ± 0.15 x10-2, 24.79 ± 0.17 x102, 25.67 ± 0.16 x10-2 and 24.51 
± 0.16 x10-2, respectively. The FP results in Table 2a demonstrate good separation between 
glioblastoma cells and normal astrocytes. Statistical analysis confirmed that the differences 
between astrocytes and glioblastoma cells were significant for all cell lines (p<0.0001). 
As shown in Table 2b, when the nuclei were excluded, Gibco-NHA and Clonetics-NHA 
had decreased average FP values of 20.43 ± 0.14 x10-2 and 21.05 ± 0.13 x10-2, respectively. 
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Glioblastoma cell lines, U87-MG, U118-MG, 5075-MG, and U251-MG exhibited average FP 
of 25.13 ± 0.13 x10-2, 24.15 ± 0.15 x10-2, 23.94 ± 0.14 x10-2, and 25.00 ± 0.15 x10-2, 
respectively. In comparison to the analysis of the entire cell, larger FP differences between 
cancer and normal cells were observed when the nuclei were excluded from the analysis. 
Therefore, excluding the nuclei from the analysis allows for better discrimination of cancer 
cells from normal cells. In addition, we analyzed the difference in fluorescence polarization 
exhibited by the nuclei of the normal and cancerous cells. The results are shown in Table 2c. 
It can be seen that the nuclei of glioblastoma cell lines, U87-MG, U118-MG, 5075-MG, and 
U251-MG presented average FP values of 25.90 ± 0.13 x10-2, 24.62 ± 0.16 x10-2, 24.45 ± 
0.14 x10-2, and 25.76 ± 0.15 x10-2, respectively. The nuclei of the Clonetics-NHA and 
Gibco-NHA exhibited average FP values of 23.08 ± 0.13 x10-2 and 22.73 ± 0.13 x10-2, 
respectively. Even though the differences of FP between cancer and normal cells that were 
observed from the nuclei are smaller in comparison to those obtained from the entire cells, 
they are still highly significant (p<0.0001). 
Previous studies have shown that MB displays a high affinity to the mitochondria [27,36], 
and it is known that mitochondria have increased relative abundance in cancer cells [27]. Our 
subcellular MB localization experiments confirmed that the degree of co-localization for MB 
and mitochondria in the cancer cells was significantly higher as compared to normal cells. 
Mitochondria display several properties consistent with this finding. In particular, the 
negatively charged inner mitochondrial membrane attracts positively charged, lipophilic 
molecules such as MB [27]. The degree of dye accumulation is proportional to the 
mitochondrial membrane potential (MMP) [27], which is increased in various pathologies 
including brain, breast, renal and pancreatic cancers [37–39]. In addition, the mitochondrial 
matrix is viscous in comparison with primarily aqueous cytoplasm [40]. Preferential uptake of 
MB by the mitochondria of the cancer cells, as well as increased viscosity within 
mitochondria may cause the observed increase in MB FP. 
As mentioned above, cancers of the brain, breast, kidney, pancreas, lung and colon are 
characterized by elevated MMP [37–39]. Therefore, these malignancies may also exhibit 
increased FP due to binding of MB to the mitochondria. Apart from the current study, our 
previous work with cultured breast cells [23] and renal FNA specimens [24] support this 
hypothesis. Overall, the MB FP technique may be capable of accurately diagnosing several 
types of cancers. However, further studies with clinical brain specimens are required to 
investigate the utility and sensitivity of MB FP for the detection of brain cancer at early 
stages. 
Our optical imaging technique is rapid, non-destructive and does not necessarily require 
tissue acquisition and processing. Viability experiments performed in this study revealed that 
the cells remained viable during and after the experiments. These characteristics point to the 
possibility of real time, in vivo detection of cancers at the cellular level. A wide range of 
clinical and research applications could utilize this technology to study the early stages of 
cancer progression in animal models, and also to evaluate new cancer drugs, treatment 
modalities and protocols. The multimodal imaging approach presents several distinct 
advantages for analysis of single cells compared to existing methods. The fluorescence 
images display morphology comparable to histology, while FP images provide a quantitative 
metric for each cell. The equipment is inexpensive and robust, while the imaging procedure is 
rapid. Due to the simplicity of data processing and interpretation, quantitative images may be 
acquired and interpreted by researchers and clinicians without extensive training. Taken 
together, these features may facilitate wide adoption of the method by cancer researchers, as 
well as life-science and medical professionals. 
5. Conclusions 
In summary, our study provided several important results. We demonstrated that human brain 
cancer cells exhibited significantly higher fluorescence polarization of methylene blue as 
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compared to normal human brain cells. Greater uptake of methylene blue by mitochondria in 
cancer cells offers an explanation for the observed increase in fluorescence polarization. 
Other cancers also exhibit increased mitochondrial membrane potential and therefore may 
also display increased fluorescence polarization of methylene blue. The results of our study 
show that the proposed imaging approach may be useful for a broad range of clinical and 
research applications in brain cancer diagnosis. 
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